## **Supporting Information**

## *In-Situ* Self-Assembling Liver Spheroids with Synthetic Nanoscaffolds for Preclinical Drug Screening Applications

Lina Wu,<sup>1</sup> Driton Vllasaliu<sup>1</sup>, Qi Cui<sup>1</sup> and Bahijja Tolulope Raimi-Abraham<sup>1\*</sup>

\* Corresponding Author: Dr Bahijja Raimi-Abraham, Bahijja.Raimi-

Abraham@kcl.ac.uk

King's College London, Faculty of Life Sciences and Medicine, School of Cancer and Pharmaceutical Sciences, Institute of Pharmaceutical Science, Franklin-Wilkins Building, 150 Stamford Street, London SE1 9NH, United Kingdom

Influence of PCL nanofibre on HepG2 cell viability and proliferation




Figure S1. Toxicity of PCL nanofibre on 2D HepG2 cells.

## Influence of Nanoscaffold Concentration on Spheroid Formation




Figure S2. HepG2 Spheroids with different concentrations of PCL nanofibres on Day 3. Scale bar: 50 µm. Objective:10X.




Figure S3. Generation of HepG2 Spheroids with and without nanoscaffolds. Scale bar: 100 µm.